Pam is a seasoned business leader with 25+ years of experience in the biopharmaceutical industry. She leads global teams, collaborating with partners to accelerate R&D and optimize the commercialization of new drugs, biologics and precision medicine platforms. She creates value at the intersection of R&D, Regulatory and Finance, specializing in M&A, in-licensing and multi-company collaborative models for rare diseases. Incorporating her knowledge of clinical trial design, data science, operations and healthcare policy has allowed her to consistently identify high-impact opportunities across oncology, neuroscience, immunology and other therapeutic areas.

Prior to joining the biopharmaceutical industry, Pam was a global institutional investor in New York and Chicago. She managed over $1 billion in equity and fixed income assets for a Wall Street portfolio management boutique and worked at a global buy-side investment firm, specializing in private placement debt.

Early in her career, she earned the Chartered Financial Analyst (CFA) distinction and practiced as a Certified Public Accountant (CPA).

Pam recently earned the National Association of Corporate Director (NACD) certification, and currently serves on the Advisory Board of Women of Color in Pharma (WOCIP). Pam has an MBA from Harvard Business School.